The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LVII.a

BAL: An excess proportion of lymphocytes

Publications

Mitropoulou G, Daccord C, Sauty A, Pasche A, Egger B, Aedo Lopez V, Letovanec I, Beigelman-Aubry C, Nicod LP, Lazor R

Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.

Respiration; international review of thoracic diseases 2020 Jan 08;;1-6 — 2020 Jan 08 — 1-6

Ishiwata T, Ebata T, Iwasawa S, Matsushima J, Ota S, Nakatani Y, Tsushima K, Tada Y, Tatsumi K, Takiguchi Y

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).

Internal medicine (Tokyo, Japan) 2017 Sep 01;56;2311-2315 — 2017 Sep 01 — 2311-2315

Diamantopoulos PT, Gaggadi M, Kassi E, Benopoulou O, Anastasopoulou A, Gogas H

Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.

Melanoma research 2017 08;27;391-395 — 2017 08 — 391-395